Caribou Biosciences Included in BioPM360’s Innovations Issue

December 17, 2017

Caribou Biosciences is pioneering the development of CRISPR gene editing technology across human therapeutics, agriculture, industrial biotech, and biological research. Since its inception, the company’s singular focus has been to advance and refine this revolutionary technology, with the ultimate goal of developing new products that have the potential to deliver profound benefits to both human health and society as a whole.

As a result of the company’s extensive IP portfolio, world-class research team, and key industry collaborations, Caribou has emerged as a leader across the CRISPR space. Since its founding in 2011, the company has raised more than $40 million in venture funding and has secured key strategic partnerships with industry leaders. In the area of human gene and cell therapies, Caribou co-founded Intellia Therapeutics in 2014 in order to utilize the power of CRISPR technology to develop curative medicines for a host of serious diseases.

Caribou has been focused on conducting cutting-edge research to overcome some of the most significant technical challenges facing CRISPR companies today. With key papers published in Nature Methods and Molecular Cell, the company is continuing to operate at the forefront of scientific discovery and has been responsible for making significant advances that will pave the way for commercialization of CRISPR products.

Looking to the future, the gene-editing technology market is projected to grow to $3.5B by 2019. As one of the pioneers of the field, Caribou is harnessing the power of CRISPR technology to accelerate the pace of biological research and to address devastating genetic diseases.